Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 188
- Registration Number
- NCT04559607
- Locations
- 🇨🇳
Zhongda Hospital, Nanjing, Jiangsu, China
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 25
- Registration Number
- NCT04548271
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 27
- Registration Number
- NCT04547088
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 23
- Registration Number
- NCT04539600
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2021-08-23
- Target Recruit Count
- 42
- Registration Number
- NCT04533490
Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT04520035
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Xuhui, China
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 294
- Registration Number
- NCT04521153
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
- Conditions
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 52
- Registration Number
- NCT04515615
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Taizhou Hospital, Taizhou, Zhejiang, China
🇨🇳The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04512417
- Locations
- 🇨🇳
Zhejiang Province Cancer Hospital, Hanzhou, Zhejiang, China
Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Qianfoshan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04507750
- Locations
- 🇨🇳
Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.